Medirom Healthcare Financials
MRM Stock | USD 0.92 0.01 1.08% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 0.45 | 0.44 |
|
|
The financial analysis of Medirom Healthcare is a critical element in measuring its lifeblood. Investors should not minimize Medirom Healthcare's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
Medirom | Select Account or Indicator |
Medirom Healthcare Stock Summary
Medirom Healthcare competes with HR Block, Service International, Rollins, WW International, and Carriage Services. MEDIROM Healthcare Technologies Inc. provides holistic healthcare services in Japan. MEDIROM Healthcare Technologies Inc. was incorporated in 2000 and is headquartered in Tokyo, Japan. MEDIROM Healthcare operates under Personal Services classification in the United States and is traded on NASDAQ Exchange. It employs 171 people.Specialization | Consumer Cyclical, Health Care Equipment & Services |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US58510H1032 |
CUSIP | 58510H103 |
Location | Japan |
Business Address | Tradepia Odaiba, Tokyo, |
Sector | Health Care Providers & Services |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | medirom.co.jp |
Phone | 81 3 6721 7364 |
Currency | USD - US Dollar |
Medirom Healthcare Key Financial Ratios
Return On Equity | 1.47 | ||||
Profit Margin | 0.02 % | ||||
Operating Margin | (0.02) % | ||||
Price To Sales | 0 X | ||||
Revenue | 6.83 B |
Medirom Healthcare Key Balance Sheet Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Total Assets | 5.7B | 5.8B | 6.7B | 6.8B | 7.9B | 6.3B | |
Other Current Liab | 1.7B | 1.9B | 2.6B | 1.6B | 1.9B | 1.6B | |
Net Debt | 463.8M | 2.4B | 1.9B | 3.5B | 4.1B | 2.3B | |
Retained Earnings | (1.7B) | (2.7B) | (2.5B) | 80.3M | 72.2M | 75.9M | |
Accounts Payable | 67.0M | 230.9M | 207.6M | 137.7M | 158.4M | 166.3M | |
Cash | 1.4B | 370.6M | 605.5M | 106.3M | 95.7M | 90.9M | |
Long Term Debt | 668.4M | 746.6M | 1.1B | 1.1B | 1.2B | 753.3M | |
Net Receivables | 148.5M | 855.3M | 534.7M | 621.9M | 559.7M | 476.9M | |
Good Will | 150.7M | 600.3M | 539.5M | 484.6M | 557.2M | 351.5M | |
Inventory | 8.0M | 18.7M | 114.1M | 140.0M | 161.0M | 169.0M | |
Other Current Assets | 458.5M | 111.2M | 1.1B | 890.0M | 1.0B | 1.1B | |
Total Liab | 5.2B | 6.0B | 6.8B | 6.6B | 7.6B | 6.1B | |
Net Invested Capital | 1.3B | 700.5M | 1.2B | 1.8B | 2.0B | 1.2B | |
Short Long Term Debt | 221.1M | 162.3M | 99.2M | 500.4M | 450.4M | 235.8M | |
Total Current Assets | 2.1B | 1.4B | 2.4B | 1.8B | 2.0B | 1.8B | |
Capital Stock | 595.1M | 1.2B | 1.2B | 20M | 23M | 21.9M | |
Net Working Capital | 428.3M | (1.8B) | (1.3B) | (1.8B) | (1.6B) | (1.7B) | |
Short Term Debt | 900.6M | 917.5M | 868.9M | 1.3B | 1.1B | 827.8M | |
Intangible Assets | 97.6M | 391.0M | 403.7M | 920.7M | 1.1B | 1.1B |
Medirom Healthcare Key Income Statement Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Tax Provision | 16.9M | 576.3M | 30.8M | (94.4M) | (108.6M) | (103.2M) | |
Net Interest Income | (12.1M) | (11.1M) | (3.7M) | (35.8M) | (32.2M) | (30.6M) | |
Interest Income | 667K | 839K | 6.1M | 1.1M | 1.3M | 2.0M | |
Interest Expense | 13.2M | 12.0M | 9.8M | 36.9M | 42.4M | 44.5M | |
Total Revenue | 3.3B | 5.4B | 7.0B | 6.8B | 7.9B | 5.5B | |
Gross Profit | 429.0M | 1.4B | 1.9B | 1.6B | 1.8B | 1.3B | |
Operating Income | (639.6M) | (379.5M) | 97.0M | (391.6M) | (352.4M) | (334.8M) | |
Ebit | (639.6M) | (379.5M) | 97.0M | 57.5M | 66.1M | 69.4M | |
Ebitda | (577.3M) | (228.1M) | 281.0M | 310.1M | 356.6M | 374.4M | |
Cost Of Revenue | 2.9B | 4.0B | 5.1B | 5.3B | 6.0B | 4.2B | |
Income Before Tax | (626.7M) | (414.5M) | 179.8M | 20.6M | 23.7M | 24.9M | |
Net Income | (539.2M) | (990.7M) | 149.0M | 115.0M | 132.3M | 138.9M | |
Income Tax Expense | 87.5M | 576.3M | 30.8M | (94.4M) | (85.0M) | (80.7M) |
Medirom Healthcare Key Cash Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Change To Inventory | (2.4M) | (2.4M) | (95.4M) | (25.9M) | (23.3M) | (24.4M) | |
Investments | 36.3M | (72.9M) | 580.4M | (328.6M) | (377.9M) | (359.0M) | |
Change In Cash | 926.1M | (1.1B) | 234.8M | (499.1M) | (449.2M) | (426.7M) | |
Free Cash Flow | (440.0M) | (671.0M) | (806.4M) | (767.6M) | (690.8M) | (725.4M) | |
Depreciation | 62.3M | 126.2M | 184.1M | 252.6M | 290.5M | 305.0M | |
Other Non Cash Items | (156.7M) | (442.3M) | (968.8M) | (1.4B) | (1.3B) | (1.2B) | |
Capital Expenditures | 73.6M | 113.8M | 120.7M | 135.8M | 156.2M | 94.1M | |
Net Income | (539.2M) | (990.7M) | 149.0M | 115.0M | 132.3M | 138.9M | |
End Period Cash Flow | 1.4B | 370.6M | 605.5M | 106.3M | 95.7M | 90.9M |
Medirom Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Medirom Healthcare's current stock value. Our valuation model uses many indicators to compare Medirom Healthcare value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Medirom Healthcare competition to find correlations between indicators driving Medirom Healthcare's intrinsic value. More Info.Medirom Healthcare Technologies is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . At this time, Medirom Healthcare's Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Medirom Healthcare by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Medirom Healthcare Systematic Risk
Medirom Healthcare's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Medirom Healthcare volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Medirom Healthcare correlated with the market. If Beta is less than 0 Medirom Healthcare generally moves in the opposite direction as compared to the market. If Medirom Healthcare Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Medirom Healthcare is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Medirom Healthcare is generally in the same direction as the market. If Beta > 1 Medirom Healthcare moves generally in the same direction as, but more than the movement of the benchmark.
Medirom Healthcare Thematic Clasifications
Medirom Healthcare Technologies is part of Personal Services investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Personal Services industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Personal Services industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Personal Services | View |
Today, most investors in Medirom Healthcare Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Medirom Healthcare's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Medirom Healthcare growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Medirom Healthcare February 2, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Medirom Healthcare help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Medirom Healthcare Technologies. We use our internally-developed statistical techniques to arrive at the intrinsic value of Medirom Healthcare Technologies based on widely used predictive technical indicators. In general, we focus on analyzing Medirom Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Medirom Healthcare's daily price indicators and compare them against related drivers.
Information Ratio | (0.18) | |||
Maximum Drawdown | 58.71 | |||
Value At Risk | (11.89) | |||
Potential Upside | 10.33 |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medirom Healthcare Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Medirom Healthcare. If investors know Medirom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Medirom Healthcare listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.582 | Earnings Share (0.15) | Revenue Per Share | Quarterly Revenue Growth (0.06) | Return On Assets |
The market value of Medirom Healthcare is measured differently than its book value, which is the value of Medirom that is recorded on the company's balance sheet. Investors also form their own opinion of Medirom Healthcare's value that differs from its market value or its book value, called intrinsic value, which is Medirom Healthcare's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Medirom Healthcare's market value can be influenced by many factors that don't directly affect Medirom Healthcare's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Medirom Healthcare's value and its price as these two are different measures arrived at by different means. Investors typically determine if Medirom Healthcare is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Medirom Healthcare's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.